An Approach to Study Prognosis of Bacille Calmette-Gu ́erin for Bladder Cancer Treatment

Authors

  • Suna Zhai First Affilicated Hospital of Zhengzhou University
  • Xiufang Lv
  • Bingyan Li
  • Pengcheng Zhou
  • Tiansong Liang

Keywords:

Bladder Cancer, BCG, Treatment

Abstract

Bladder cancer is a common cancer in the world. One treatment approach, Bacille Calmette Gu ́erin (BCG), has been used for more than 30 years. There is no prognosis biomarker for BCG treatment. Here we used public data to screen candidate genes as biomarkers for BCG prognosis, presenting the dry-lab way for scientific study which is cost-effective especially for researchers with limited resources. The candidates need further verification on its potential. Sensitive prognosis markers would help more precisive BCG application, which may promote BCG application where it is still limited.

References

Wit M, Retz MM, R ̈odel C, Gschwend JE. The Diagnosis and Treatment of Patients With Bladder Carcinoma. Dtsch Arztebl Int. 2020;118. https: //doi.org/10.3238/arztebl.m2021.0013.

Retz M, Karl A. [Bladder cancer : Current diagnosis and treatment modal- ities]. Urologe A. 2018;57:655–656. https://doi.org/10.1007/s00120-018-0 651-1.

DeGeorge KC, Holt HR, Hodges SC. Bladder Cancer: Diagnosis and Treatment. Am Fam Physician. 2017;96:507–514.

JRCO 2021

Del Giudice F, Busetto GM, Gross MS, Maggi M, Sciarra A, Salciccia S, et al. Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single- institution cohort analysis. J Cancer Res Clin Oncol. 2021;147:3073–3080. https://doi.org/10.1007/s00432-021-03571-0.

Pan J, Liu M, Zhou X. Can intravesical bacillus Calmette-Gu ́erin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis. Front Med. 2014;8:241–9. https://doi.org/ 10.1007/s11684-014-0328-0.

Han RF, Pan JG. Can intravesical bacillus Calmette-Gu ́erin reduce recur- rence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67:1216–23. https://doi.org/10.1016/j.ur ology.2005.12.014.

Lamm DL. Efficacy and safety of bacille Calmette-Gu ́erin immunotherapy in superficial bladder cancer. Clin Infect Dis. 2000;31 Suppl 3:S86–90. https://doi.org/10.1086/314064.

LiK,LinT,XueW,MuX,XuE,YangX,etal. Currentstatusof diagnosis and treatment of bladder cancer in China - Analyses of Chinese Bladder Cancer Consortium database. Asian J Urol. 2015;2:63–69. https: //doi.org/10.1016/j.ajur.2015.04.016.

Sanders JA, Frasier C, Matulay JT, Steuerwald NM, Zhu J, Grigg CM, et al. Genomic analysis of response to bacillus Calmette-Gu ́erin (BCG) treatment in high-grade stage 1 bladder cancer patients. Transl Androl Urol. 2021;10:2998–3009. https://doi.org/10.21037/tau-21-158.

Downloads

Published

2021-09-22 — Updated on 2021-09-23

Versions